Title

Decreasing Unnecessary Pharmacy Cost in the Cath Lab

Authors

Scott M. Scepaniak, St. Cloud Hospital, CentraCare HealthFollow
Kristi Patterson, St. Cloud Hospital, CentraCare HealthFollow

Files

Description

AngioMax is a single dose heparin alternative introduced in 2002 that is used in cardiac patients undergoing percutaneous intervention (PCI). Bivalirudin costs $377 per dose; heparin is less than $15 per dose. Noting practice variations, the Cath Lab set out to eliminate unnecessary pharmacy cost for PCI patients by:

• Using current literature to inform clinical care
• Standardizing practice
• Using data to track and guide implementation

Publication Date

2018

Keywords

Bivaliruidin, Heparin, Cost, Percutaneous intervention, Standardized practice

Disciplines

Cardiology | Other Nursing | Pharmacoeconomics and Pharmaceutical Economics

Comments

2018 Nurses Week Poster

Recommended Citation

Scepaniak, Scott M. and Patterson, Kristi, "Decreasing Unnecessary Pharmacy Cost in the Cath Lab" (2018). Nursing Posters. 103.
https://digitalcommons.centracare.com/nursing_posters/103